
Akil A. Merchant, MD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
310-423-1160

- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Akil A. Merchant, MD
Scheduling
In person visits
Samuel Oschin Cancer Center
127 S San Vicente Blvd - 7th Floor
Los Angeles, CA
34.074713 -118.379418From You
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

Akil A. Merchant, MD
Languages
- English,
Gender
Male
Experience
22 Years
Locations
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
2
- Research
- IM Hematology Oncology
Sub Specialties
A focused area of clinical knowledge and skills within a specialty. Example: a neurology specialist focused on stroke treatment.
3
- Stem Cell Transplantation
- Lymphoma
- CAR T Cell Therapy
Programs
Cedars-Sinai clinical programs this provider is part of:
2
Research Areas
Akil Merchant, MD, is an NIH funded physician-scientist who focuses on developing new treatments for blood cancers such as leukemia and lymphoma. In particular, he studies how interactions between tumor cells, cancer stem cells and the tumor immune microenvironment can drive the progression of tumors and resistance to chemotherapies. The work in the lab is organized in two major themes: 1) Hedgehog signaling in normal and malignant hematopoiesis. Currently we have two projects in the lab focused on Hedgehog signaling. The first is focused on understanding how loss of Gli2 and Gli3 disrupts stem cell function in normal hematopoietic stem cells. The aim of the second project is to understand how mutant JAK/STAT (JAK2V617F) signaling interacts with Hh/Smo activity in myeloproliferative neoplasms to drive fibrosis in the bone marrow. 2) Multiplex Imaging of the Tumor Microenvironment (TME). Dr. Merchant is a leader in applying imaging mass cytometry (IMC) to the study of the tumor immune microenvironment and is the founding director of the IMC Shared Resources Core at Cedars-Sinai. IMC is a novel imaging technology that allows for the simultaneous measurement of over 40 proteins in a single slice of tissue, at single cell resolution. Ultimately our goal is better understand the immune response to cancer so we can predict which patients will respond to treatment with immuno-oncology drugs and identify new immuno-oncology targets in the future.
Titles
- Director, Imaging Mass Cytometry Shared Resource
- Associate Professor, Medicine
Education & Training
-
Johns Hopkins University
Fellowship - Completed 2010
-
Baylor College of Medicine
Residency - Completed 2005
-
Baylor College of Medicine
Medical School - Completed 2000
Achievements
-
1
Board Certifications
Board Certifications
-
IM/Oncology
American Board of Internal Medicine